2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients Trilaciclib, carboplatin, etoposideļ¼or Topotecan, placebo, carboplatin, etoposideļ¼or Topotecan - Extensive-stage Small-cell Lung Cancer | Phase 3 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 95 | 2021-05-25 | 2024-07-10 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) Trilaciclib, Placebo, Gemcitabine - TNBC - Triple-Negative Breast Cancer, Breast Cancer | Phase 3 | Completed | G1 Therapeutics, Inc. | 194 | 2021-05-14 | 2024-08-01 |
Breast Neoplasms (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
G1 Therapeutics, Inc. (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1)
China (2) · Australia (1) · Bulgaria (1) · France (1) · Georgia (1) · Moldova (1) · Poland (1) · Russia (1) · Spain (1) · Ukraine (1) · United States (1)